Table 2 Existing PMF treatments (from [28, 34]) in significant connection set
From: QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Drug | Comments | Cell lines |
|---|---|---|
Anagrelide | Significant negative connections found | ASC, NPC |
Azacitidine | Significant negative connections found | VCAP, PC3, MCF7 |
Busulfan | No significant negative connections found | |
Cytarabine | No significant negative connections found | HA1E, PC3, A549, MCF7, VCAP |
(indicative negative connections found) | ||
Danazol | Significant negative connections found | PHH, ASC |
Decitabine | No significant negative connections found | |
Epoetin-alpha | No data in LINCS set | |
Everolimus | Significant negative connections found | A549, ASC, HT29 |
Hydroxyurea | No data in LINCS set | |
Interferon alpha | No data in LINCS set | |
Lenalidomide | Significant negative connections found | SNUC4, A375, COV644 |
Melphalan | No significant negative connections found | HA1E |
(indicative negative connection found) | ||
Mercaptopurine | Significant negative connection found | MCF7 |
Methylprednisolone | Significant negative connection found | A549 |
Pomalidomide | No data in LINCS set | |
Prednisone | No significant negative connections found | |
Ruxolitinib | Significant negative connection found | HEPG2 |
Thalidomide | Significant negative connections found | TYKNU, PHH, CL34, HCC515 |
Thioguanine | No data in LINCS set |